![]() |
ARIZONA STATE SENATE
Fifty-Seventh Legislature, First Regular Session
appropriation; ibogaine; clinical research study
Purpose
Appropriates $5,000,000 from the state General Fund (state GF) in FY 2026 to the Department of Health Services (DHS) to award a grant to conduct a certified clinical research study on the use of ibogaine for the treatment of neurological diseases.
Background
DHS must advance research in the state relating to the: 1) causes, epidemiology and diagnosis of diseases; 2) formulation of cure for diseases; and 3) development of medically accepted treatment and prevention of diseases, including the discovery and development of new drugs (A.R.S. ยง 36-272).
Post-traumatic stress disorder is a mental health condition that is triggered by either experiencing or witnessing a terrifying event. Symptoms may start within one month of a traumatic event but may not appear until years later. Symptoms may include flashbacks, nightmares, severe anxiety and uncontrollable thoughts about the event (Mayo Clinic).
H.B. 2871 appropriates $5,000,000 from the state GF in FY 2026 to DHS.
Provisions
1. Appropriates $5,000,000 from the state GF in FY 2026 to DHS to award grants to conduct a certified clinical research study on the use of ibogaine for the treatment of neurological diseases that includes traumatic brain injury and post-traumatic stress disorder.
2. Requires DHS to award grants only to an entity that has:
a) a history of proven research and treatment of neurological diseases;
b) a neurosurgery program with the requisite clinical and research facilities and that is staffed by professionals having expertise in the most challenging neurological and neurosurgical conditions;
c) the ability to facilitate pioneering research and innovation in diagnosis and treatment of neurological conditions; and
d) demonstrated to DHS that the entity has a commitment of matching monies of gifts, grants and donations from sources other than the state of at least $5,000,000 to conduct the study.
3. Exempts the appropriation from lapsing.
4. Becomes effective on the general effective date.
House Action
APPROP 2/24/25 DPA 13-1-4-0
3rd Read 3/3/25 36-22-2
Prepared by Senate Research
March 6, 2025
LMM/ci